Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00569543 · ClinicalTrials.gov registry record

Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Treated for Newly Diagnosed Breast Cancer

A clinical trial of Breast Cancer, sponsored by University of Nebraska.

Completed
Registry status
27
Enrollment target
2
Study locations

NCT00569543 is a study of Breast Cancer that has completed, run by University of Nebraska. The registered enrollment target is 27 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00569543, a study of Breast Cancer, has completed, sponsored by University of Nebraska.

COMPLETED
Registry status
27 participants
Enrollment target
2
Study locations

Study Summary

RATIONALE: Studying samples of urine in the laboratory from women with breast cancer may help doctors learn whether tamoxifen and aromatase inhibitors alter the metabolism of estrogens. PURPOSE: This clinical trial is studying the effect of tamoxifen or an aromatase inhibitor on estrogen metabolism in women undergoing treatment for newly diagnosed breast cancer.

Conditions Studied

Interventions

  • OTHER laboratory biomarker analysis
  • OTHER medical chart review
  • OTHER high performance liquid chromatography
  • OTHER mass spectrometry

Study Locations (2)

Minnesota

  • Mayo Clinic Cancer Center - Rochester

Nebraska

  • Eppley Cancer Center at University of Nebraska Medical Center - Omaha

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2005-05-11
Est. Completion 2012-08-02

Sponsor

University of Nebraska

407 total trials

What the Registry Record Tells You About NCT00569543

The ClinicalTrials.gov registry entry for NCT00569543 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which laboratory biomarker analysis is the first listed.

NCT00569543 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Minnesota, Nebraska.

Frequently Asked Questions

What is clinical trial NCT00569543 about?

NCT00569543 is a clinical study titled "Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Treated for Newly Diagnosed Breast Cancer". RATIONALE: Studying samples of urine in the laboratory from women with breast cancer may help doctors learn whether tamoxifen and aromatase inhibitors alter the metabolism of estrogens. PURPOSE: This clinical trial is studying the effect of tamoxifen or an aromatase inhibitor on estrogen metabolism...

What is the current status of trial NCT00569543?

This trial is currently completed. The enrollment target is 27 participants. The study started on 2005-05-11. Estimated completion is 2012-08-02.

What conditions does trial NCT00569543 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00569543?

The interventions under investigation include: laboratory biomarker analysis (OTHER), medical chart review (OTHER), high performance liquid chromatography (OTHER), mass spectrometry (OTHER).

Who is sponsoring clinical trial NCT00569543?

This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00569543 being conducted?

This trial has 2 study locations across Minnesota, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.